valsartan has been researched along with Angiogenesis, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harbig, J; Jaworski, K; Miller, AG; Tan, G; Wilkinson-Berka, JL | 1 |
| Akino, M; Chiba, S; Kitabatake, A; Kumamoto, H; Matsui, Y; Mikami, T; Nan, J; Okamoto, H; Onozuka, H; Shimizu, T; Sugawara, T | 1 |
2 other study(ies) available for valsartan and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology.
Topics: Aldosterone; Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Animals; Cattle; Cells, Cultured; Cytokines; Endothelial Cells; Eye Proteins; Glucosephosphate Dehydrogenase; Leukostasis; Mineralocorticoid Receptor Antagonists; NADPH Oxidase 4; NADPH Oxidases; Neovascularization, Pathologic; Oxidative Stress; Oxygen; Pericytes; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Renin-Angiotensin System; Retinal Vasculitis; Sodium Chloride; Spironolactone; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2009 |
VEGF-mediated angiogenesis is impaired by angiotensin type 1 receptor blockade in cardiomyopathic hamster hearts.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomyopathies; Cricetinae; Enalapril; Endothelial Growth Factors; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Neovascularization, Pathologic; Receptor, Angiotensin, Type 1; RNA, Messenger; Tetrazoles; Time Factors; Valine; Valsartan; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |